{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:14:07Z","timestamp":1778717647968,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":24,"publisher":"Springer US","isbn-type":[{"value":"9781071650400","type":"print"},{"value":"9781071650417","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5041-7_19","type":"book-chapter","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:52:04Z","timestamp":1778716324000},"page":"399-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions"],"prefix":"10.1007","author":[{"given":"Carina Lynn","family":"Gehlert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothee","family":"Winterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammelie Svea","family":"Boje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Theocharis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Jochimsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Klausz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"4","key":"19_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278\u2013287","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"19_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter PJ, Lazar GA (2018) Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019. Nat Rev Drug Discov 17(3):197\u2013223","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"19_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/antib9040064","volume":"9","author":"R Liu","year":"2020","unstructured":"Liu R et al (2020) Fc-engineering for modulated effector functions-improving antibodies for cancer treatment. Antibodies (Basel) 9(4):64","journal-title":"Antibodies (Basel)"},{"issue":"9","key":"19_CR4","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields RL et al (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591\u2013604","journal-title":"J Biol Chem"},{"issue":"5","key":"19_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/bit.20151","volume":"87","author":"N Yamane-Ohnuki","year":"2004","unstructured":"Yamane-Ohnuki N et al (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.\u00a0Biotechnol Bioeng 87(5):614\u2013622","journal-title":"Biotechnol Bioeng"},{"issue":"11","key":"19_CR6","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1073\/pnas.0508123103","volume":"103","author":"GA Lazar","year":"2006","unstructured":"Lazar GA et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103(11):4005\u20134010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"19_CR7","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","volume":"67","author":"JB Stavenhagen","year":"2007","unstructured":"Stavenhagen JB et al (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 67(18):8882\u20138890","journal-title":"Cancer Res"},{"issue":"6","key":"19_CR8","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/bcr3069","volume":"13","author":"JL Nordstrom","year":"2011","unstructured":"Nordstrom JL et al (2011) Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res 13(6):R123","journal-title":"Breast Cancer Res"},{"issue":"4","key":"19_CR9","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.4049\/jimmunol.166.4.2571","volume":"166","author":"EE Idusogie","year":"2001","unstructured":"Idusogie EE et al (2001) Engineered antibodies with increased activity to recruit complement. J\u00a0Immunol 166(4):2571\u20132575","journal-title":"J Immunol"},{"issue":"2","key":"19_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4161\/mabs.2.2.11158","volume":"2","author":"GL Moore","year":"2010","unstructured":"Moore GL et al (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2(2):181\u2013189","journal-title":"MAbs"},{"issue":"6176","key":"19_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder CA et al (2014) Complement is activated by IgG hexamers assembled at the cell surface. Science 343(6176):1260\u20131263","journal-title":"Science"},{"issue":"10","key":"19_CR12","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1158\/0008-5472.CAN-07-6297","volume":"68","author":"A Natsume","year":"2008","unstructured":"Natsume A et al (2008) Engineered antibodies of IgG1\/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 68(10):3863\u20133872","journal-title":"Cancer Res"},{"issue":"1","key":"19_CR13","doi-asserted-by":"publisher","first-page":"e1002344","DOI":"10.1371\/journal.pbio.1002344","volume":"14","author":"RN de Jong","year":"2016","unstructured":"de Jong RN et al (2016) A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol 14(1):e1002344","journal-title":"PLoS Biol"},{"issue":"1","key":"19_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s42003-021-02513-3","volume":"4","author":"JM Sopp","year":"2021","unstructured":"Sopp JM et al (2021) On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation. Commun Biol 4(1):1031","journal-title":"Commun Biol"},{"issue":"5","key":"19_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000479978","volume":"44","author":"T Wirt","year":"2017","unstructured":"Wirt T et al (2017) An Fc double-engineered CD20 antibody with enhanced ability to trigger complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. Transfus Med Hemother 44(5):292\u2013300","journal-title":"Transfus Med Hemother"},{"issue":"4","key":"19_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/antib9040063","volume":"9","author":"S Ro\u00dfkopf","year":"2020","unstructured":"Ro\u00dfkopf S et al (2020) Enhancing CDC and ADCC of CD19 antibodies by combining Fc protein-engineering with Fc glyco-engineering. Antibodies (Basel) 9(4):63","journal-title":"Antibodies (Basel)"},{"key":"19_CR17","first-page":"44","volume-title":"A laboratory manual, vol 579","author":"E Harlow","year":"1988","unstructured":"Harlow E, Lane D (1988) A laboratory manual, vol 579. Cold Spring Harbor Laboratory, New York, 44"},{"issue":"8","key":"19_CR18","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.4049\/jimmunol.1200501","volume":"190","author":"A Lux","year":"2013","unstructured":"Lux A et al (2013) Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 190(8):4315\u20134323","journal-title":"J Immunol"},{"key":"19_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/978-1-4939-8648-4_20","volume":"1827","author":"C Kellner","year":"2018","unstructured":"Kellner C et al (2018) Fc Glyco- and Fc protein-engineering: design of antibody variants with improved ADCC and CDC activity. Methods Mol Biol 1827:381\u2013397","journal-title":"Methods Mol Biol"},{"key":"19_CR20","doi-asserted-by":"publisher","first-page":"929339","DOI":"10.3389\/fimmu.2022.929339","volume":"13","author":"T Zeller","year":"2022","unstructured":"Zeller T et al (2022) Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages. Front Immunol 13:929339","journal-title":"Front Immunol"},{"key":"19_CR21","first-page":"88","volume":"65","author":"MR Clark","year":"1997","unstructured":"Clark MR (1997) IgG effector mechanisms. Chem Immunol 65:88\u2013110","journal-title":"Chem Immunol"},{"issue":"13","key":"19_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1182\/blood-2017-01-764316","volume":"130","author":"DM Schewe","year":"2017","unstructured":"Schewe DM et al (2017) An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts. Blood 130(13):1543\u20131552","journal-title":"Blood"},{"key":"19_CR23","doi-asserted-by":"publisher","first-page":"957874","DOI":"10.3389\/fimmu.2022.957874","volume":"13","author":"CL Gehlert","year":"2022","unstructured":"Gehlert CL et al (2022) Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody. Front Immunol 13:957874","journal-title":"Front Immunol"},{"issue":"2","key":"19_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.beha.2011.03.004","volume":"24","author":"M Peipp","year":"2011","unstructured":"Peipp M, van de Winkel JG, Valerius T (2011) Molecular engineering to improve antibodies' anti-lymphoma activity. Best Pract Res Clin Haematol 24(2):217\u2013229","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Methods in Molecular Biology","Antibody Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5041-7_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:52:05Z","timestamp":1778716325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5041-7_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650400","9781071650417"],"references-count":24,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5041-7_19","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"14 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}